NASDAQ:CBIO Crescent Biopharma Q1 2026 Earnings Report $17.95 -0.24 (-1.32%) Closing price 06/16/2026 04:00 PM EasternExtended Trading$18.25 +0.30 (+1.69%) As of 07:03 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Crescent Biopharma EPS ResultsActual EPS-$0.70Consensus EPS -$0.85Beat/MissBeat by +$0.15One Year Ago EPSN/ACrescent Biopharma Revenue ResultsActual Revenue$1.04 millionExpected Revenue$0.36 millionBeat/MissBeat by +$682.00 thousandYoY Revenue GrowthN/ACrescent Biopharma Announcement DetailsQuarterQ1 2026Date4/29/2026TimeAfter Market ClosesConference Call DateN/AConference Call TimeN/AUpcoming EarningsCrescent Biopharma's next earnings date is estimated for Thursday, July 30, 2026, based on past reporting schedules. Conference Call ResourcesEarnings HistoryCompany Profile Crescent Biopharma Earnings HeadlinesCrescent Biopharma Announces Grants of Inducement AwardsJune 11, 2026 | globenewswire.comCrescent Biopharma, Inc. (NASDAQ:CBIO) Given Consensus Recommendation of "Buy" by BrokeragesJune 7, 2026 | americanbankingnews.comTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no debate, no vote, one executive order. Gold tripled within three years and climbed 20x over the following decade. Trump holds that same executive authority today, and his advisors are openly saying a reversal is on the table. There are two ways this plays out - both move gold in the same direction. A free briefing breaks down exactly what Nixon did, why Trump is positioned to act, and how to move your 401k into gold before any announcement - tax free.June 17 at 1:00 AM | Reagan Gold Group (Ad)Crescent Biopharma shareholders back directors, pay and auditorJune 6, 2026 | theglobeandmail.comAnalysts Are Bullish on These Healthcare Stocks: Crescent Biopharma (CBIO), IQVIA Holdings (IQV)June 4, 2026 | theglobeandmail.comCrescent Biopharma, Inc. to Present at Jefferies and Goldman Sachs Healthcare Conferences in June 2026June 2, 2026 | quiverquant.comQSee More Crescent Biopharma Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Crescent Biopharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Crescent Biopharma and other key companies, straight to your email. Email Address About Crescent BiopharmaCrescent Biopharma (NASDAQ:CBIO) (NASDAQ: CBIO) is a clinical‐stage immuno‐oncology company focused on the discovery, development and commercialization of novel therapies for patients with solid tumors. The company’s research strategy centers on combination approaches that enhance anti‐tumor immune responses by simultaneously targeting multiple pathways implicated in immune evasion and tumor growth. The company’s lead candidate, CPB-201, is a bifunctional fusion protein designed to block programmed death-ligand 1 (PD-L1) while neutralizing transforming growth factor-beta (TGF-β), with the goal of restoring T-cell activity and reducing tumor fibrosis. In parallel, Crescent is advancing an oncolytic adenovirus program engineered to selectively infect and lyse cancer cells, thereby releasing tumor antigens and amplifying systemic immune responses. Additional preclinical assets explore complementary mechanisms to address resistance in solid tumors. Research and development activities are conducted primarily in the United States, leveraging a proprietary platform that integrates molecular engineering with immuno‐oncology expertise. Crescent collaborates with contract research organizations and academic institutions to optimize candidate selection, advance preclinical studies and prepare for clinical evaluation. Founded in 2020 and headquartered in Woodland Hills, California, Crescent Biopharma is led by a management team and scientific advisory board with extensive experience in oncology drug discovery, biologics development and clinical operations. The company is focused on progressing its pipeline through IND-enabling studies and early‐phase clinical trials.View Crescent Biopharma ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Okta’s AI Moment May Be Bigger Than Investors RealizeStrategy’s Bitcoin Rally Has a Hidden EngineIs Lennar Finally Turning the Corner After Its Housing Slump?Can D-Wave Hold Its Own Against 2 Fast-Growing Rivals?This Golden Cross Could Send Urban Outfitters to New Highs3 Dividend Increases Investors Can Actually TrustRH’s Strong Q1 Still Leaves Investors With One Big Question Upcoming Earnings Accenture (6/18/2026)FedEx (6/23/2026)Micron Technology (6/24/2026)NIKE (6/30/2026)PepsiCo (7/9/2026)Delta Air Lines (7/9/2026)Fastenal (7/13/2026)Bank of America (7/14/2026)The Goldman Sachs Group (7/14/2026)JPMorgan Chase & Co. (7/14/2026) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
